GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardiff Oncology Inc (STU:XE7C) » Definitions » Cyclically Adjusted PB Ratio

Cardiff Oncology (STU:XE7C) Cyclically Adjusted PB Ratio : 0.11 (As of May. 21, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cardiff Oncology Cyclically Adjusted PB Ratio?

As of today (2024-05-21), Cardiff Oncology's current share price is €3.265. Cardiff Oncology's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €28.81. Cardiff Oncology's Cyclically Adjusted PB Ratio for today is 0.11.

The historical rank and industry rank for Cardiff Oncology's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:XE7C' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.03   Med: 0.07   Max: 0.7
Current: 0.12

During the past years, Cardiff Oncology's highest Cyclically Adjusted PB Ratio was 0.70. The lowest was 0.03. And the median was 0.07.

STU:XE7C's Cyclically Adjusted PB Ratio is ranked better than
87.04% of 648 companies
in the Biotechnology industry
Industry Median: 1.745 vs STU:XE7C: 0.12

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Cardiff Oncology's adjusted book value per share data for the three months ended in Mar. 2024 was €1.253. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €28.81 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Cardiff Oncology Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Cardiff Oncology's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiff Oncology Cyclically Adjusted PB Ratio Chart

Cardiff Oncology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.55 0.18 0.04 0.05

Cardiff Oncology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.04 0.04 0.05 0.18

Competitive Comparison of Cardiff Oncology's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Cardiff Oncology's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardiff Oncology's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cardiff Oncology's Cyclically Adjusted PB Ratio falls into.



Cardiff Oncology Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Cardiff Oncology's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=3.265/28.81
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiff Oncology's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Cardiff Oncology's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.253/131.7762*131.7762
=1.253

Current CPI (Mar. 2024) = 131.7762.

Cardiff Oncology Quarterly Data

Book Value per Share CPI Adj_Book
201406 48.579 100.560 63.659
201409 36.516 100.428 47.914
201412 25.776 99.070 34.286
201503 64.491 99.621 85.307
201506 46.733 100.684 61.165
201509 118.403 100.392 155.419
201512 108.247 99.792 142.941
201603 89.353 100.470 117.195
201606 69.236 101.688 89.722
201609 56.133 101.861 72.619
201612 43.956 101.863 56.864
201703 23.217 102.862 29.743
201706 7.240 103.349 9.231
201709 6.254 104.136 7.914
201712 7.498 104.011 9.500
201803 4.644 105.290 5.812
201806 5.187 106.317 6.429
201809 3.131 106.507 3.874
201812 2.313 105.998 2.876
201903 1.894 107.251 2.327
201906 1.439 108.070 1.755
201909 0.939 108.329 1.142
201912 0.766 108.420 0.931
202003 0.505 108.902 0.611
202006 1.015 108.767 1.230
202009 1.083 109.815 1.300
202012 2.864 109.897 3.434
202103 2.792 111.754 3.292
202106 2.915 114.631 3.351
202109 2.870 115.734 3.268
202112 2.961 117.630 3.317
202203 2.728 121.301 2.964
202206 2.632 125.017 2.774
202209 2.639 125.227 2.777
202212 2.247 125.222 2.365
202303 2.017 127.348 2.087
202306 1.789 128.729 1.831
202309 1.632 129.860 1.656
202312 1.431 129.419 1.457
202403 1.253 131.776 1.253

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cardiff Oncology  (STU:XE7C) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Cardiff Oncology Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Cardiff Oncology's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardiff Oncology (STU:XE7C) Business Description

Traded in Other Exchanges
Address
11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.

Cardiff Oncology (STU:XE7C) Headlines

No Headlines